Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens
Eli Lilly shares fell 0.4% after hours to $1,077.19 as the FDA told drugmakers to remove suicide warnings from GLP-1 weight-loss drugs, including Lilly’s Zepbound. At the JPMorgan Healthcare Conference, Lilly and rivals pitched new obesity pills and longer-acting shots, with Lilly targeting a second-quarter U.S. approval for its oral drug. Amgen and Novo Nordisk highlighted new data and launches in the crowded obesity market.